Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 61, Issue 1, 2008, Pages 99-106

  Lobato, J V ^a,b   Mauricio A C ^b   Rodrigues, J M ^b,c   Cavaleiro, M V ^b   Cortez, P P ^b   Xavier, L ^a   Botelho, C ^b,d   Hussain, N Sooraj ^b,d   Santos, J D ^b,d  

^a CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Avascular osteonecrosis; Bisphosphonates; Jaw; Multiple myeloma

Indexed keywords

AMOXICILLIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ERYTHROPOIETIN; THALIDOMIDE; ZOLEDRONIC ACID;

ACTINOMYCES ISRAELII; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; AVASCULAR NECROSIS; BIOPSY; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HUMAN; HYPERCALCEMIA; JAW AVASCULAR OSTEONECROSIS; MALE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; OSTEOLYSIS; PAIN; PANORAMIC RADIOGRAPHY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RISK ASSESSMENT; SPINAL CORD COMPRESSION; TOOTH EXTRACTION;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MANDIBULAR DISEASES; MULTIPLE MYELOMA; OSTEONECROSIS; RADIOGRAPHY, PANORAMIC;

EID: 36649035515     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2006.06.016     Document Type: Article

References (39)

1. Mundy G.R., and Bertoline D.R. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 13 3 (1986) 291-299
2. Belch A.R., Bergsagel D.E., Wilson K., et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9 8 (1991) 1397-1402
3. Kyle R.A., Jowsey J., and Kelly P.J. Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med 293 26 (1975) 1334-1338
4. Kyle R.A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 50 1 (1975) 29-40
5. Roodman G.D. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32 2 (2004) 290-292
6. Berenson J.R. Myeloma bone disease. Best Pract Res Clin Haematol 18 4 (2005) 653-672
7. Ruggerio S.L., Mekrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
8. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanism of action. J Clin Invest 97 12 (1996) 2692-2696
9. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27 3 (2001) 165-176
10. Sietsema W.K., Ebetino F.H., Salvagno A.M., et al. Antiresorptive dose-response relationship across three generations of bisphosphonates. Drugs Exp Clin Res 15 9 (1989) 389-396
11. Schenk R., Eggli P., Fleisch H., et al. Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat. Calcif Tissue Int 38 (1986) 342-349
12. Jung A., Bisaz S., and Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11 4 (1973) 269-280
13. Coukell A.J., and Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumor-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12 2 (1998) 149-168
14. Hughes D.E., MacDonald B.R., Russel R.G.G., et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83 6 (1989) 1930-1935
15. Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 10 (1995) 1478-1487
16. Murakami H., Takahashi N., Sasaki T., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17 2 (1995) 137-144
17. Sahni M., Guenther H.L., Fleisch H., et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91 5 (1993) 2004-2011
18. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 1 (1998) 80-100
19. Shinoda H., Adamek G., Félix R., et al. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 35 1 (1983) 87-99
20. Pereira J., Mancini I., and Walker P. The role of bisphosphonates in malignant bone pain: a review. J Palliat Care 14 2 (1998) 25-36
21. Purohit O.P., Radstone C.R., Anthony C., et al. A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer 72 5 (1995) 1289-1293
22. Hillner B.E., Ingle J.N., and Chlebowski R.T. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 21 (2003) 4042-4057 [Erratum in J Clin Oncol 2004;22(7):1351]
23. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18 6 (2000) 1378-1391
24. Lacerna L., and Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumours. Semin Oncol 30 5 Suppl. 16 (2003) 150-160
25. Lipton A., Costa L., Ali S., et al. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28 4 Suppl. 11 (2001) 54-59
26. Brincker H., Westin J., Abildgaard N., et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish Co-operative Study Group. Br J Haematol 101 2 (1998) 3280-3286
27. Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16 7 (1998) 593-602
28. Berenson J.R., Vescio R.A., Lee S.R., et al. Phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7 3 (2001) 478-485
29. Van Poznak C.H. The use of bisphosphonates in patients with breast cancer. Cancer Control 9 6 (2002) 480-489
30. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 9 (2003) 1115-1117
31. Vannucchi A.M., Ficarra G., Antonioli E., et al. Osteonecrosis of the jaw associated with zoledronate therapy in patient with multiple myeloma. Br J Haematol 128 6 (2005) 738-739
32. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 9 (2003) 1104-1107
33. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182 8 (2005) 417-418
34. Carter G., Goss A.N., and Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 182 8 (2005) 413-415
35. Durie B., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99-102
36. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 22 (2003) 4253-4254
37. Robinson N.A., and Yeo J.F. Bisphosphonates - a word of caution. Ann Acad Med Singapore 33 4 (2004) 48-49
38. Starck W.J., and Epker B.N. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10 1 (1995) 74-78
39. Melo M., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 2 (2005) 111-113